BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 30209067)

  • 1. Zebrafish blastomere screen identifies retinoic acid suppression of
    Mandelbaum J; Shestopalov IA; Henderson RE; Chau NG; Knoechel B; Wick MJ; Zon LI
    J Exp Med; 2018 Oct; 215(10):2673-2685. PubMed ID: 30209067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Oncogenic Transcriptional Regulator MYB in Adenoid Cystic Carcinoma by Inhibition of IGF1R/AKT Signaling.
    Andersson MK; Afshari MK; Andrén Y; Wick MJ; Stenman G
    J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28954282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UM-HACC-2A: MYB-NFIB fusion-positive human adenoid cystic carcinoma cell line.
    Warner KA; Oklejas AE; Pearson AT; Zhang Z; Wu W; Divi V; Rodriguez-Ramirez C; Castilho RM; Polverini PJ; Nör JE
    Oral Oncol; 2018 Dec; 87():21-28. PubMed ID: 30527239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Establishment of PDX-derived salivary adenoid cystic carcinoma cell lines using organoid culture method.
    Takada K; Aizawa Y; Sano D; Okuda R; Sekine K; Ueno Y; Yamanaka S; Aoyama J; Sato K; Kuwahara T; Hatano T; Takahashi H; Arai Y; Nishimura G; Taniguchi H; Oridate N
    Int J Cancer; 2021 Jan; 148(1):193-202. PubMed ID: 32984947
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multiplex preclinical model for adenoid cystic carcinoma of the salivary gland identifies regorafenib as a potential therapeutic drug.
    Chen C; Choudhury S; Wangsa D; Lescott CJ; Wilkins DJ; Sripadhan P; Liu X; Wangsa D; Ried T; Moskaluk C; Wick MJ; Glasgow E; Schlegel R; Agarwal S
    Sci Rep; 2017 Sep; 7(1):11410. PubMed ID: 28900283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study of MYB-NFIB chimeric gene expression, tumor angiogenesis, and proliferation in adenoid cystic carcinoma of salivary gland.
    Ono J; Okada Y
    Odontology; 2018 Jul; 106(3):238-244. PubMed ID: 29243184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYB-NFIB gene fusions identified in archival adenoid cystic carcinoma tissue employing NanoString analysis: an exploratory study.
    McIntyre JB; Ko JJ; Siever J; Chan AMY; Simpson RHW; Hao D; Lau HY
    Diagn Pathol; 2019 Jul; 14(1):78. PubMed ID: 31301736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYB-activated models for testing therapeutic agents in adenoid cystic carcinoma.
    Jiang Y; Gao R; Cao C; Forbes L; Li J; Freeberg S; Fredenburg KM; Justice JM; Silver NL; Wu L; Varma S; West R; Licht JD; Zajac-Kaye M; Kentsis A; Kaye FJ
    Oral Oncol; 2019 Nov; 98():147-155. PubMed ID: 31606723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance.
    Mitani Y; Li J; Rao PH; Zhao YJ; Bell D; Lippman SM; Weber RS; Caulin C; El-Naggar AK
    Clin Cancer Res; 2010 Oct; 16(19):4722-31. PubMed ID: 20702610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MYB promotes the growth and metastasis of salivary adenoid cystic carcinoma.
    Xu LH; Zhao F; Yang WW; Chen CW; Du ZH; Fu M; Ge XY; Li SL
    Int J Oncol; 2019 May; 54(5):1579-1590. PubMed ID: 30896785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma.
    Brayer KJ; Frerich CA; Kang H; Ness SA
    Cancer Discov; 2016 Feb; 6(2):176-87. PubMed ID: 26631070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYB fusions and CD markers as tools for authentication and purification of cancer stem cells from salivary adenoid cystic carcinoma.
    Panaccione A; Zhang Y; Ryan M; Moskaluk CA; Anderson KS; Yarbrough WG; Ivanov SV
    Stem Cell Res; 2017 May; 21():160-166. PubMed ID: 28500913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MYB and MYBL1 in adenoid cystic carcinoma: diversity in the mode of genomic rearrangement and transcripts.
    Togashi Y; Dobashi A; Sakata S; Sato Y; Baba S; Seto A; Mitani H; Kawabata K; Takeuchi K
    Mod Pathol; 2018 Jun; 31(6):934-946. PubMed ID: 29410490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of Myb protein and downstream target genes in salivary adenoid cystic carcinoma.
    Bell D; Roberts D; Karpowicz M; Hanna EY; Weber RS; El-Naggar AK
    Cancer Biol Ther; 2011 Oct; 12(7):569-73. PubMed ID: 21785271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and characterization of xenograft model systems for adenoid cystic carcinoma.
    Moskaluk CA; Baras AS; Mancuso SA; Fan H; Davidson RJ; Dirks DC; Golden WL; Frierson HF
    Lab Invest; 2011 Oct; 91(10):1480-90. PubMed ID: 21709671
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An oncogenic MYB feedback loop drives alternate cell fates in adenoid cystic carcinoma.
    Drier Y; Cotton MJ; Williamson KE; Gillespie SM; Ryan RJ; Kluk MJ; Carey CD; Rodig SJ; Sholl LM; Afrogheh AH; Faquin WC; Queimado L; Qi J; Wick MJ; El-Naggar AK; Bradner JE; Moskaluk CA; Aster JC; Knoechel B; Bernstein BE
    Nat Genet; 2016 Mar; 48(3):265-72. PubMed ID: 26829750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Profiling and the Impact of Treatment on Outcomes in Adenoid Cystic Carcinoma Type I and II.
    Hanna GJ; Grover P; Elliott A; McGrath J; Xiu J; Sukari A; Johnson JM; Wise-Draper T
    Clin Cancer Res; 2024 May; 30(10):2225-2232. PubMed ID: 38416410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104).
    Ho AL; Foster NR; Deraje Vasudeva S; Katabi N; Antonescu CR; Frenette GP; Pfister DG; Erlichman C; Schwartz GK
    Cancer; 2024 Mar; 130(5):702-712. PubMed ID: 37947157
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MYB, MYBL1, MYBL2 and NFIB gene alterations and MYC overexpression in salivary gland adenoid cystic carcinoma.
    Fujii K; Murase T; Beppu S; Saida K; Takino H; Masaki A; Ijichi K; Kusafuka K; Iida Y; Onitsuka T; Yatabe Y; Hanai N; Hasegawa Y; Inagaki H
    Histopathology; 2017 Nov; 71(5):823-834. PubMed ID: 28594149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteasome inhibitors suppress MYB oncogenic activity in a p300-dependent manner.
    Yusenko MV; Biyanee A; Andersson MK; Radetzki S; von Kries JP; Stenman G; Klempnauer KH
    Cancer Lett; 2021 Nov; 520():132-142. PubMed ID: 34256093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.